Shionogi & Co., Ltd. (SGIOY)

Market Cap	13.21B
Revenue (ttm)	2.91B
Net Income (ttm)	1.07B
Shares Out	n/a
EPS (ttm)	1.26
PE Ratio	12.31
Forward PE	n/a
Dividend	0.79 (10.15%)
Ex-Dividend Date	Mar 28, 2025

Volume	6
Average Volume	69,248
Open	7.44
Previous Close	7.61
Day's Range	7.44 - 7.76
52-Week Range	6.22 - 8.59
Beta	0.22
RSI	54.62
Earnings Date	May 12, 2025

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,959
• Stock Exchange: OTCMKTS
• Ticker Symbol: SGIOY

Financial Performance

In 2023, Shionogi &'s revenue was 435.08 billion, an increase of 1.97% compared to the previous year's 426.68 billion. Earnings were 162.03 billion, a decrease of -12.40%.

Financial numbers in JPY